- inflammatory Breast Ca- More aggressive; it is a Clinical Diagnosis (not a pathological one) - Staging usually includes bone scan; CT head only performed if focal neuro findings. - CA 27.29, 15-3 are used to monitor response/recurrence of disease (Not used for Diagnosis) - debate within the guidelines of whether to use
Posted 11/03/16 09:14:11 AM by Adam Faye
Bisphosphonates (Rank-Ligand inhibitors as well) have been shown to decrease prevalence of skeletal-related events/hyperCa in Breast Ca. More recently, may be useful for limiting bone mets.
Anthracyclines are associated with cardiomyopathy (dose dependent) and have increased likelihood of secondary malignancies.
Paclitaxel (microtubule inhibitor) is associated with peripheral neuropathy.
Posted 11/03/16 09:27:24 AM by Adam Faye
Hormone positive metastatic breast cancer:
Palbociclib (CDK 4/6 inhibitor) - has shown to prolong progression free survival when combined with fulvestrant (estrogen receptor antagonist)
Ribociclib - newer agent (similar to palbociclib in mechanism and toxicity) - looked at patients receiving initial systemic treatment for HR+, HER2 (-) breast cancer.